Risvodetinib demonstrated to be safe and well-tolerated with preliminary clinical benefits Risvodetinib demonstrated to be the first treatment to reduce alpha-synuclein pathology, widely recognized as ...
ATLANTA and BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine ...
The MarketWatch News Department was not involved in the creation of this content. SynuSight Biotech has licensed (18) F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein ...
ATLANTA and BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine ...
ATLANTA and BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- ABLi Therapeutics ("ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine ...
President John Mahama will lead the executive arm of government to attend a high profile three day international conference on leadership in Africa. Dubbed the African Biblical Leadership Initiative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results